NAD(+)What was measured
Measured, with no finding
382 endpoints
Show what was measuredHide what was measured
favorable response
increases, n = 26
Within this cohort of 26 patients, 8 of 26 (31%) responded favorably to NADH in contrast to 2 of 26 (8%) to placebo
PMID 10071523 · one of two readings recorded this
proportion of CFS patients who responded favorably, response criterion not stated in the abstract (questionnaire, laboratory and physical examination data at 4, 8 and 12 weeks)
increases, 8 of 26 (31%) responded to NADH vs 2 of 26 (8%) to placebo, n = 26
Not recorded as a finding: the paper never states the instrument the node requires
Within this cohort of 26 patients, 8 of 26 (31%) responded favorably to NADH in contrast to 2 of 26 (8%) to placebo.
PMID 10071523 · one of two readings recorded this
proportion of chronic fatigue syndrome patients responding favorably, global responder rate
increases, 8 of 26 (31%) on NADH vs 2 of 26 (8%) on placebo, n = 26
Not recorded as a finding: this platform holds no node for the endpoint
Within this cohort of 26 patients, 8 of 26 (31%) responded favorably to NADH in contrast to 2 of 26 (8%) to placebo.
PMID 10071523 · one of two readings recorded this
cognitive test measures (Cog Screen and other computer-administered tests)
increases, p = 0.05
Individuals who received NADH performed significantly better on 4 cognitive test measures (P < or = .05) and reported less sleepiness compared with those who received placebo
PMID 12385067 · one of two readings recorded this
jet lag-induced cognitive performance on four unnamed computer-administered test measures (Cog Screen) and self-reported sleepiness, morning and afternoon after an overnight flight
increases, NADH performed significantly better on 4 cognitive test measures (P < or = .05) and reported less sleepiness than placebo
Not recorded as a finding: this platform holds no node for the endpoint
Individuals who received NADH performed significantly better on 4 cognitive test measures (P < or = .05) and reported less sleepiness compared with those who received placebo.
PMID 12385067 · one of two readings recorded this
performance on 4 computer-administered cognitive test measures (Cog Screen) and self-reported sleepiness after jet lag
increases, significantly better on 4 cognitive test measures and less sleepiness vs placebo
Not recorded as a finding: this platform holds no node for the endpoint
Individuals who received NADH performed significantly better on 4 cognitive test measures (P < or = .05) and reported less sleepiness compared with those who received placebo.
PMID 12385067 · one of two readings recorded this
sleepiness
decreases
Individuals who received NADH performed significantly better on 4 cognitive test measures (P < or = .05) and reported less sleepiness compared with those who received placebo
PMID 12385067 · one of two readings recorded this
elevated IgG and IgE antibody levels
Elevated IgG and Ig E antibody levels were found in a significant number of patients
PMID 15377055 · one of two readings recorded this
mean symptom score from a fatigue and other-symptoms questionnaire, per trimester
decreases, dramatic and statistically significant reduction of the mean symptom score in the first trimester in the NADH group, p < 0.001; similar in both groups thereafter, n = 12
Not recorded as a finding: the comparison was against another active treatment
The twelve patients who received NADH had a dramatic and statistically significant reduction of the mean symptom score in the first trimester (p < 0.001).
PMID 15377055 · one of two readings recorded this
mean symptom score
decreases, p = 0.001
The twelve patients who received NADH had a dramatic and statistically significant reduction of the mean symptom score in the first trimester (p < 0.001)
PMID 15377055 · one of two readings recorded this
mean symptom score
no effect
However, symptom scores in the subsequent trimesters of therapy were similar in both treatment groups
PMID 15377055 · one of two readings recorded this
glucose-stimulated insulin secretion regulated by Sirt1 via Ucp2 repression
decreases
Here, we report that as this same cohort of BESTO mice reaches 18-24 months of age, the GSIS regulated by Sirt1 through repression of Ucp2 is blunted.
PMID 18005249 · one of two readings recorded this
GSIS and glucose tolerance
increases
Furthermore, NMN administration restores enhanced GSIS and improved glucose tolerance in the aged BESTO females, suggesting that Sirt1 activity decreases with advanced age due to a decline in systemic NAD biosynthesis.
PMID 18005249 · one of two readings recorded this
plasma nicotinamide mononucleotide (NMN)
decreases
Interestingly, plasma levels of nicotinamide mononucleotide (NMN), an important metabolite for the maintenance of normal NAD biosynthesis and GSIS in beta cells, are significantly reduced in aged BESTO mice.
PMID 18005249 · one of two readings recorded this
time and distance run before exhaustion
no effect, n = 24
The time and distance run before exhaustion was similar in the three groups (data not shown), around 600 meters after 40 minutes of exercise
PMID 19262508 · one of two readings recorded this
brain NAD(+) levels and ischemic infarct size
increases
Administration of nicotinamide (200 mg/kg, i.p.) up to 1 h after the onset of ischemia elevated brain NAD(+) levels and reduced ischemic infarct size.
PMID 19288225 · one of two readings recorded this
cellular NAD(P)H levels and mitochondrial membrane potential
decreases
Excitotoxic activation of NMDA receptors induced a rapid decrease of cellular NAD(P)H levels and mitochondrial membrane potential.
PMID 19288225 · one of two readings recorded this
glutamate/NMDA-induced NAD(+) depletion and death
no effect
Treatment of neurons with the SIRT1 activator resveratrol did not protect them from glutamate/NMDA-induced NAD(+) depletion and death.
PMID 19288225 · one of two readings recorded this
NAD(+) levels and PAR accumulation timing
decreases
Decreased NAD(+) levels and poly (ADP-ribose) polymer (PAR) accumulation in nuclei were relatively early events (<4 h) that preceded the appearance of propidium iodide- and TUNEL-positive cells
PMID 19288225 · one of two readings recorded this
NAD(+) levels, PAR accumulation and neuronal death
increases
NAD(+) levels were preserved and PAR accumulation and neuronal death induced by excitotoxic insults were attenuated in nicotinamide-treated cells.
PMID 19288225 · one of two readings recorded this
NAD(+) levels
decreases
In a mouse model of focal cerebral ischemic stroke, NAD(+) levels were decreased in both the contralateral and ipsilateral cortex 6 h after the onset of ischemia.
PMID 19288225 · one of two readings recorded this
SIRT1 deacetylase activity
decreases
Nicotinamide, an NAD(+) precursor and an inhibitor of SIRT1 and PARP1, inhibited SIRT1 deacetylase activity without affecting SIRT1 protein levels.
PMID 19288225 · one of two readings recorded this
serum adiponectin
no effect
Adiponectin levels were similar for wild-type, AMPKα1−/−, and AMPKα2−/− mice and were not changed by resveratrol
PMID 19934007 · one of two readings recorded this
body weight curve, high-fat diet vs resveratrol
decreases, p = 0.003
The body weight curves between high-fat diet and resveratrol were statistically significant for wild-type (P = 0.003) and AMPKα2−/− (P = 0.02) mice
PMID 19934007 · one of two readings recorded this
body weight curve, high-fat diet vs resveratrol
decreases, p = 0.02
The body weight curves between high-fat diet and resveratrol were statistically significant for wild-type (P = 0.003) and AMPKα2−/− (P = 0.02) mice
PMID 19934007 · one of two readings recorded this
body weight
no effect
Resveratrol reduced the body weight of wild-type and AMPKα2−/− mice but not that of AMPKα1−/− mice
PMID 19934007 · one of two readings recorded this
fasting insulin
decreases
However, resveratrol dramatically decreased the fasting insulin levels in wild-type, AMPKα1−/−, and AMPKα2−/− mice even though resveratrol increased insulin sensitivity only in wild-type mice
PMID 19934007 · one of two readings recorded this
fat mass index
unclear, p = 0.07
# P = 0.07 between high-fat diet and resveratrol for AMPKα2−/− mice
PMID 19934007 · one of two readings recorded this
glucose tolerance curve
increases, p = 0.001
Glucose tolerance curves between high-fat diet and resveratrol were significant for wild-type mice (P = 0.001) but not for AMPKα1−/− (P = 0.8) and AMPKα2−/− (P = 0.053) mice
PMID 19934007 · one of two readings recorded this
glucose tolerance curve
no effect, p = 0.8
Glucose tolerance curves between high-fat diet and resveratrol were significant for wild-type mice (P = 0.001) but not for AMPKα1−/− (P = 0.8) and AMPKα2−/− (P = 0.053) mice
PMID 19934007 · one of two readings recorded this
glucose tolerance curve
no effect, p = 0.053
Glucose tolerance curves between high-fat diet and resveratrol were significant for wild-type mice (P = 0.001) but not for AMPKα1−/− (P = 0.8) and AMPKα2−/− (P = 0.053) mice
PMID 19934007 · one of two readings recorded this
insulin sensitivity curve
increases, p = 0.01
Insulin sensitivity curves between high-fat diet (●) and resveratrol (○) were significant for wild-type (WT) mice (P = 0.01)
PMID 19934007 · one of two readings recorded this
intramyocellular DAG and ceramide
decreases
As shown in Fig. 4 D and E, resveratrol decreased DAG and ceramide levels in wild-type mice but not in AMPKα1−/− and AMPKα2−/− mice
PMID 19934007 · one of two readings recorded this
metabolic rate (Vo2)
increases
Resveratrol increased the metabolic rate of wild-type mice, but it did not increase the metabolic rate of AMPKα1−/− mice
PMID 19934007 · one of two readings recorded this
mitochondrial content (cytochrome C and mtDNA)
increases
Consistent with this, resveratrol increased the mitochondrial content, as measured by cytochrome C and mitochondrial DNA levels, in wild-type muscle but not in AMPKα1−/− or AMPKα2−/− muscle
PMID 19934007 · one of two readings recorded this
NAD and NAD-to-NADH ratio in skeletal muscle
no effect
NAD and the NAD-to-NADH ratio in skeletal muscle were increased by resveratrol in wild-type mice but not in AMPKα1−/− or AMPKα2−/− mice
PMID 19934007 · one of two readings recorded this
NAD and NAD-to-NADH ratio in skeletal muscle
increases
NAD and the NAD-to-NADH ratio in skeletal muscle were increased by resveratrol in wild-type mice but not in AMPKα1−/− or AMPKα2−/− mice
PMID 19934007 · one of two readings recorded this
NAD-to-NADH ratio
increases
As shown in Fig. 5 A, resveratrol increased the NAD-to-NADH ratio by >30%
PMID 19934007 · one of two readings recorded this
PGC-1α acetylation
decreases
As shown in Fig. 5 C, resveratrol decreased the acetylation level of PGC-1α only in wild-type mice
PMID 19934007 · one of two readings recorded this
physical endurance (treadmill distance)
increases
As reported previously, resveratrol increased physical endurance (309.2 ± 37 vs. 212.3 ± 19 m) of wild-type mice
PMID 19934007 · one of two readings recorded this
physical endurance
no effect
However, resveratrol did not increase the physical endurance of AMPKα1−/− or AMPKα2−/− mice
PMID 19934007 · one of two readings recorded this
ROS level in skeletal muscle
decreases
Resveratrol reduced ROS levels in wild-type mice by almost 30% but not in AMPKα1−/− or AMPKα2−/− mice
PMID 19934007 · one of two readings recorded this
anxiety condition (instrument not stated) and maximum heart rate after a stress test
decreases, anxiety -1.0 points (p<0.05) in the NADH group vs -0.2 points (p=NS) in the placebo group, each a within-group change
Not recorded as a finding: the result compares a group with itself, not with a control
Administration of NADH was associated to a decrease in anxiety condition of -1.0 points (p<0.05) and of -0.2 points (p=NS) in the placebo assigned group.
PMID 20447621 · one of two readings recorded this
anxiety condition score change, instrument not named in the abstract
decreases, -1.0 points on NADH vs -0.2 points (p=NS) on placebo
Not recorded as a finding: the paper never states the instrument the node requires
Administration of NADH was associated to a decrease in anxiety condition of -1.0 points (p<0.05) and of -0.2 points (p=NS) in the placebo assigned group.
PMID 20447621 · one of two readings recorded this
anxiety condition
decreases, p = 0.05
Administration of NADH was associated to a decrease in anxiety condition of -1.0 points (p<0.05) and of -0.2 points (p=NS) in the placebo assigned group
PMID 20447621 · one of two readings recorded this
anxiety condition
no effect
Administration of NADH was associated to a decrease in anxiety condition of -1.0 points (p<0.05) and of -0.2 points (p=NS) in the placebo assigned group
PMID 20447621 · one of two readings recorded this
maximum heart rate after stress test
decreases, p = 0.05
Maximum heart rate after the stress test decreased a mean of -8.1l/min (p<0.05) in the NADH group and increased by +1.7l/min in the placebo group (p=0.73)
PMID 20447621 · one of two readings recorded this
maximum heart rate after stress test
no effect, p = 0.73
Maximum heart rate after the stress test decreased a mean of -8.1l/min (p<0.05) in the NADH group and increased by +1.7l/min in the placebo group (p=0.73)
PMID 20447621 · one of two readings recorded this
glucose intolerance and lipid profiles in age-induced T2D mice
decreases
Furthermore, NAD(+) and NAMPT levels show significant decreases in multiple organs during aging, and NMN improves glucose intolerance and lipid profiles in age-induced T2D mice.
PMID 21982712 · one of two readings recorded this
glucose intolerance and NAD(+) levels in HFD-induced T2D mice
decreases
Strikingly, nicotinamide mononucleotide (NMN), a product of the NAMPT reaction and a key NAD(+) intermediate, ameliorates glucose intolerance by restoring NAD(+) levels in HFD-induced T2D mice.
PMID 21982712 · one of two readings recorded this
hepatic insulin sensitivity
increases
NMN also enhances hepatic insulin sensitivity and restores gene expression related to oxidative stress, inflammatory response, and circadian rhythm, partly through SIRT1 activation.
PMID 21982712 · one of two readings recorded this
NAD(+) and NAMPT levels across organs
decreases
Furthermore, NAD(+) and NAMPT levels show significant decreases in multiple organs during aging, and NMN improves glucose intolerance and lipid profiles in age-induced T2D mice.
PMID 21982712 · one of two readings recorded this
NAD(+) biosynthesis (NAMPT-mediated) in metabolic organs
decreases
Here, we show that NAMPT-mediated NAD(+) biosynthesis is severely compromised in metabolic organs by high-fat diet (HFD).
PMID 21982712 · one of two readings recorded this
intracellular cAMP
increases
Here, we report that the metabolic effects of resveratrol result from competitive inhibition of cAMP-degrading phosphodiesterases, leading to elevated cAMP levels.
PMID 22304913 · one of two readings recorded this
intracellular NAD(+)
increases
As a consequence, resveratrol increases NAD(+) and the activity of Sirt1.
PMID 22304913 · one of two readings recorded this
metabolic benefits (diet-induced obesity, mitochondrial function, physical stamina, glucose tolerance) in mice
increases
Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, physical stamina, and glucose tolerance in mice.
PMID 22304913 · one of two readings recorded this
Sirt1 activity
increases
As a consequence, resveratrol increases NAD(+) and the activity of Sirt1.
PMID 22304913 · one of two readings recorded this
AMPK activation
increases
A high dose of resveratrol activated AMPK in a SIRT1-independent manner, demonstrating that resveratrol dosage is a critical factor
PMID 22560220 · one of two readings recorded this
skeletal muscle NAD(+) levels
increases
Mice treated with a moderate dose of resveratrol showed increased mitochondrial biogenesis and function, AMPK activation, and increased NAD(+) levels in skeletal muscle, whereas SIRT1 knockouts displayed none of these benefits
PMID 22560220 · one of two readings recorded this
skeletal muscle NAD(+) levels
no effect
Mice treated with a moderate dose of resveratrol showed increased mitochondrial biogenesis and function, AMPK activation, and increased NAD(+) levels in skeletal muscle, whereas SIRT1 knockouts displayed none of these benefits
PMID 22560220 · one of two readings recorded this
mitochondrial-encoded OXPHOS subunits
decreases
We show that, during aging, there is a specific loss of mitochondrial, but not nuclear, encoded OXPHOS subunits
PMID 24360282 · one of two readings recorded this
mitochondrial function
increases
Deleting SIRT1 accelerates this process, whereas raising NAD(+) levels in old mice restores mitochondrial function to that of a young mouse in a SIRT1-dependent manner
PMID 24360282 · one of two readings recorded this
BAL injury indices
decreases
FK-866-mediated iNAMPT inhibition successfully reduced lung tissue iNAD levels, BAL injury indices, inflammatory cell infiltration, and lung injury scores in LPS- and VILI-exposed mice
PMID 24588101 · one of two readings recorded this
inflammatory cell infiltration
decreases
FK-866-mediated iNAMPT inhibition successfully reduced lung tissue iNAD levels, BAL injury indices, inflammatory cell infiltration, and lung injury scores in LPS- and VILI-exposed mice
PMID 24588101 · one of two readings recorded this
lung injury scores
decreases
FK-866-mediated iNAMPT inhibition successfully reduced lung tissue iNAD levels, BAL injury indices, inflammatory cell infiltration, and lung injury scores in LPS- and VILI-exposed mice
PMID 24588101 · one of two readings recorded this
lung tissue iNAD level
decreases
FK-866-mediated iNAMPT inhibition successfully reduced lung tissue iNAD levels, BAL injury indices, inflammatory cell infiltration, and lung injury scores in LPS- and VILI-exposed mice
PMID 24588101 · one of two readings recorded this
PMN apoptosis (caspase-3 activation in BAL PMNs)
increases
FK-866 further increased lung PMN apoptosis, as reflected by caspase-3 activation in BAL PMNs
PMID 24588101 · one of two readings recorded this
early- and late-stage disease progression
decreases
This vitamin effectively delayed early- and late-stage disease progression, by robustly inducing mitochondrial biogenesis in skeletal muscle and brown adipose tissue, preventing mitochondrial ultrastructure abnormalities and mtDNA deletion formation
PMID 24711540 · one of two readings recorded this
mitochondrial biogenesis
increases
This vitamin effectively delayed early- and late-stage disease progression, by robustly inducing mitochondrial biogenesis in skeletal muscle and brown adipose tissue, preventing mitochondrial ultrastructure abnormalities and mtDNA deletion formation
PMID 24711540 · one of two readings recorded this
mitochondrial ultrastructure abnormalities and mtDNA deletion formation
decreases
This vitamin effectively delayed early- and late-stage disease progression, by robustly inducing mitochondrial biogenesis in skeletal muscle and brown adipose tissue, preventing mitochondrial ultrastructure abnormalities and mtDNA deletion formation
PMID 24711540 · one of two readings recorded this
mitochondrial unfolded protein response
increases
NR further stimulated mitochondrial unfolded protein response, suggesting its protective role in mitochondrial disease
PMID 24711540 · one of two readings recorded this
LDL cholesterol and 1-carbon metabolism
no effect
NR also did not elevate low density lipoprotein cholesterol or dysregulate 1-carbon metabolism
PMID 31278280 · one of two readings recorded this
whole blood NAD+
increases
Consumption of 100, 300 and 1000 mg NR dose-dependently and significantly increased whole blood NAD+ (i.e., 22%, 51% and 142%) and other NAD+ metabolites within 2 weeks
PMID 31278280 · one of two readings recorded this
whole blood NAD+
increases
Consumption of 100, 300 and 1000 mg NR dose-dependently and significantly increased whole blood NAD+ (i.e., 22%, 51% and 142%) and other NAD+ metabolites within 2 weeks
PMID 31278280 · one of two readings recorded this
whole blood NAD+
increases
Consumption of 100, 300 and 1000 mg NR dose-dependently and significantly increased whole blood NAD+ (i.e., 22%, 51% and 142%) and other NAD+ metabolites within 2 weeks
PMID 31278280 · one of two readings recorded this
circulating inflammatory cytokines
decreases, n = 12
NR also depressed levels of circulating inflammatory cytokines
PMID 31412242 · one of two readings recorded this
skeletal muscle energy metabolism and mitochondria pathway gene expression
decreases, n = 12
Muscle RNA sequencing revealed NR-mediated downregulation of energy metabolism and mitochondria pathways, without altering mitochondrial bioenergetics
PMID 31412242 · one of two readings recorded this
skeletal muscle mitochondrial bioenergetics
no effect, n = 12
Muscle RNA sequencing revealed NR-mediated downregulation of energy metabolism and mitochondria pathways, without altering mitochondrial bioenergetics
PMID 31412242 · one of two readings recorded this
skeletal muscle NAD+ metabolome (NAAD and nicotinamide clearance products)
increases, n = 12
Targeted metabolomics showed that NR elevated the muscle NAD+ metabolome, evident by increased nicotinic acid adenine dinucleotide and nicotinamide clearance products
PMID 31412242 · one of two readings recorded this
lymphocyte tail DNA percentage (TD)
no effect, p = 0.05
However, no significant difference was observed between the groups (p > 0.05)
PMID 32545655 · one of two readings recorded this
lymphocyte tail DNA percentage (TD)
increases, p = 0.05
TD was significantly increased in all groups at IAE rather than at IBE and significantly decreased at 30 MAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
lymphocyte tail length (TL)
increases, p = 0.05
both CC + MF and CC + HF groups exhibited significantly higher values than the T + HF group at 30 MAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
lymphocyte tail length (TL)
increases, p = 0.05
the TL was significantly higher in the CC + MF group than in the T + HF group at IAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
lymphocyte tail length (TL)
increases, p = 0.05
All groups showed a significant increase in TL at IAE rather than at IBE and significantly reduced at 30 MAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
lymphocyte tail moment (TM)
increases, p = 0.05
TM of the CC + MF group was significantly higher than that of the CC + HF and T + HF groups at IAE and 30 MAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
lymphocyte tail moment (TM)
increases, p = 0.05
TM was significantly higher in the T + MF group than in the T + HF group at IAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
lymphocyte tail moment (TM)
increases, p = 0.05
TM was significantly higher in all groups at the IAE rather than at the IBE and significantly decreased at 30 MAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
plasma lactate
no effect, p = 0.05
no significant difference was observed between the groups (p > 0.05)
PMID 32545655 · one of two readings recorded this
plasma lactate
increases, p = 0.05
All groups displayed a significant increase in plasma lactate levels at IAE rather than at IBE and significant reduction at 30 MAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
plasma MDA
increases, p = 0.05
plasma MDA levels were significantly higher in the CC + MF group than in the T + HF group at IAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
plasma MDA
increases, p = 0.05
All groups displayed a significant increase in plasma MDA levels at IAE rather than at IBE, and the CC + HF and T + HF groups presented a significant reduction at 30 MAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
plasma SOD activity
no effect, p = 0.05
However, no significant difference was observed between the groups (p > 0.05)
PMID 32545655 · one of two readings recorded this
plasma SOD activity
increases, p = 0.05
Plasma SOD activity was significantly increased in all groups at IAE rather than at IBE and significantly decreased at 30 MAE (p < 0.05)
PMID 32545655 · one of two readings recorded this
ALP 0 h and 48 h by Step
ALP (U/l) | 109.8 ± 47.2 | 105.0 ± 33.9 | 116.3 ± 64.4 | 143.5 ± 62.9 | 148.0 ± 120.2 | 117.3 ± 65.1 | 86.3 ± 39.7 | 91.3 ± 38.5 | 79.8 ± 29.3 | 111.6 ± 37.3
PMID 32791973 · one of two readings recorded this
ALT 0 h and 48 h by Step
ALT (U/l) | 14.5 ± 3.9 | 13.0 ± 1.4 | 24.5 ± 7.1 | 103.0 ± 117.4 | 15.8 ± 3.1 | 18.8 ± 5.7 | 20.2 ± 12.1 | 23.0 ± 15.7 | 15.6 ± 7.5 | 18.0 ± 6.7
PMID 32791973 · one of two readings recorded this
AST 0 h and 48 h by Step
AST (U/l) | 20.0 ± 6.6 | 19.5 ± 2.1 | 25.0 ± 9.8 | 60.5 ± 55.9 | 33.8 ± 12.7 | 33.0 ± 2.8 | 27.2 ± 8.6 | 27.7 ± 17.8 | 25.6 ± 13.3 | 24.0 ± 1.9
PMID 32791973 · one of two readings recorded this
blood urea nitrogen (NRPT vs placebo)
decreases
Blood urea nitrogen (BUN) was lower at 48 h in patients treated with NRPT compared to placebo
PMID 32791973 · one of two readings recorded this
BUN 0 h and 48 h by Step
BUN (mg/dl) | 45.0 ± 28.1 | 63.5 ± 29.0 | 36.8 ± 15.6 | 34.6 ± 12.1 | 33.5 ± 9.3 | 28.0 ± 13.1 | 35.6 ± 12.6 | 37.3 ± 9.3 | 28.4 ± 12.0 | 28.6 ± 16.2
PMID 32791973 · one of two readings recorded this
creatinine and eGFR (NRPT vs placebo)
no effect
Compared to placebo, there was no significant difference in creatinine and eGFR in patients treated with NRPT at 48 h
PMID 32791973 · one of two readings recorded this
eGFR 0 h and 48 h by Step
eGFR (ml/min/1.73m2) | 41.3 ± 21.1 | 25.0 ± 7.1 | 43.2 ± 9.9 | 47.8 ± 11.5 | 42.0 ± 20.4 | 50.0 ± 28.1 | 39.2 ± 13.3 | 41.3 ± 15.7 | 46.4 ± 21.8 | 43.6 ± 17.5
PMID 32791973 · one of two readings recorded this
hemoglobin 0 h and 48 h by Step
Hgb (g/dl) | 11.0 ± 2.0 | 9.9 ± 3.1 | 10.9 ± 2.9 | 11.4 ± 3.0 | 11.1 ± 3.3 | 10.8 ± 3.3 | 10.3 ± 1.7 | 10.7 ± 1.5 | 11.3 ± 2.0 | 11.1 ± 2.4
PMID 32791973 · one of two readings recorded this
platelet count 0 h and 48 h by Step
PLT (K/μl) | 207.3 ± 37.3 | 225.5 ± 17.7 | 202.8 ± 68.7 | 240.0 ± 28.1 | 260.5 ± 74.5 | 234.3 ± 59.4 | 286.0 ± 136.7 | 238.0 ± 74.7 | 268.3 ± 75.6 | 269.0 ± 108.4
PMID 32791973 · one of two readings recorded this
serum creatinine 0 h and 48 h by Step
Cr (mg/dl) | 1.52 ± 0.45 | 1.95 ± 0.40 | 1.66 ± 0.27 | 1.62 ± 0.33 | 1.62 ± 0.48 | 1.56 ± 0.64 | 1.9 ± 0.69 | 1.79 ± 0.84 | 1.54 ± 0.41 | 1.62 ± 0.51
PMID 32791973 · one of two readings recorded this
serum potassium 0 h and 48 h by Step
K (mEq/l) | 4.1 ± 0.4 | 4.0 ± 0.1 | 4.2 ± 0.5 | 4.6 ± 0.9 | 4.3 ± 0.4 | 4.1 ± 0.2 | 4.2 ± 0.5 | 4.5 ± 0.5 | 4.3 ± 0.5 | 4.3 ± 0.5
PMID 32791973 · one of two readings recorded this
serum sodium 0 h and 48 h by Step
Na (mEq/l) | 140.0 ± 2.2 | 138.5 ± 0.7 | 140.6 ± 3.5 | 138.8 ± 5.1 | 140.0 ± 2.9 | 138.3 ± 2.5 | 140.6 ± 3.6 | 140.0 ± 2.9 | 137.2 ± 3.3 | 136.2 ± 2.6
PMID 32791973 · one of two readings recorded this
WBC 0 h and 48 h by Step
WBC (K/μl) | 6.9 ± 3.4 | 8.5 ± 1.4 | 8.9 ± 2.1 | 9.0 ± 1.8 | 10.1 ± 2.9 | 9.2 ± 2.0 | 9.3 ± 2.8 | 8.2 ± 2.3 | 10.2 ± 5.7 | 8.8 ± 2.5
PMID 32791973 · one of two readings recorded this
whole blood NAD+
unclear, p = 0.19
NPRT treatment (all Steps combined) demonstrated an 80% increase in NAD+ levels compared to placebo at 48 h, although this difference was not statistically significant (p = 0.19)
PMID 32791973 · one of two readings recorded this
whole blood NAD+
increases, p = 0.04
only the increase with NRPT Step 2 (dose 500 mg/100 mg) reached statistical significance (47%, p = 0.04)
PMID 32791973 · one of two readings recorded this
whole blood NAD+
unclear
The highest mean increase in NAD+ was achieved in Step 3 (67%, dose 750 mg/150 mg), but this increase was not statistically significant
PMID 32791973 · one of two readings recorded this
whole blood NAD+
increases, p = 0.002
NRPT treatment demonstrated a significant increase in whole blood NAD+ levels at 48 h compared to baseline (37%, p = 0.002)
PMID 32791973 · one of two readings recorded this
whole blood NAD+
decreases, p = 0.05
whole blood NAD+ levels in patients with AKI receiving placebo decreased by 50% at 48 h (p = 0.05, Fig. 3a)
PMID 32791973 · one of two readings recorded this
mean arterial pressure
no effect, p = 0.653
Day 1 | 102 (97–107) | 103 (97–109) | 0.653
PMID 34191033 · one of two readings recorded this
mean arterial pressure
no effect, p = 0.976
Day 15 | 102 (97–107) | 102 (96–108) | 0.976
PMID 34191033 · one of two readings recorded this
mean arterial pressure
no effect, p = 0.738
Day 29 | 99.4 (93.5–105) | 98.5 (94.0–103) | 0.738
PMID 34191033 · one of two readings recorded this
basal metabolic rate
no effect, p = 0.824
Basal metabolic rates and fasting RERs were similar between INT and CON (P = 0.824 and P = 0.297, respectively
PMID 34191033 · one of two readings recorded this
body fat percentage
no effect, p = 0.121
34.2% (95% CI: 29.3%, 39.2%) and 33.3% (95% CI: 27.6%, 38.9%), respectively; P = 0.121
PMID 34191033 · one of two readings recorded this
body weight
no effect, p = 0.812
Body weight did not differ between INT (73.0 kg; 95% CI: 68.6 kg, 77.5 kg) and CON (72.9 kg; 95% CI: 68.6 kg,77.2 kg; P = 0.812)
PMID 34191033 · one of two readings recorded this
cycling carbohydrate oxidation rate
no effect, p = 0.186
nor did cycling RER, carbohydrate oxidation, or lipid oxidation rates (P = 0.366, 0.186, and 0.466, respectively; Figure 5F–H)
PMID 34191033 · one of two readings recorded this
cycling lipid oxidation rate
no effect, p = 0.466
nor did cycling RER, carbohydrate oxidation, or lipid oxidation rates (P = 0.366, 0.186, and 0.466, respectively; Figure 5F–H)
PMID 34191033 · one of two readings recorded this
cycling respiratory exchange ratio
no effect, p = 0.366
nor did cycling RER, carbohydrate oxidation, or lipid oxidation rates (P = 0.366, 0.186, and 0.466, respectively; Figure 5F–H)
PMID 34191033 · one of two readings recorded this
cytochrome C response
no effect, p = 0.368
CytC responses were, on average, 1.32% for INT and 0.73% for CON, and did not differ between conditions (P = 0.368)
PMID 34191033 · one of two readings recorded this
diastolic blood pressure
no effect, p = 0.551
Day 1 | 82.9 (77.6–88.2) | 84.3 (80.0–88.6) | 0.551
PMID 34191033 · one of two readings recorded this
diastolic blood pressure
no effect, p = 0.733
Day 15 | 82.9 (78.1–87.8) | 83.8 (78.5–89.0) | 0.733
PMID 34191033 · one of two readings recorded this
diastolic blood pressure
no effect, p = 0.433
Day 29 | 81.1 (75.1–87.0) | 79.4 (74.8–84.1) | 0.433
PMID 34191033 · one of two readings recorded this
ex vivo State 2 respiration (malate + glutamate)
unclear, p = 0.01
although a slight but significant difference of malate + glutamate (MG; P = 0.010) was observed between INT and CON
PMID 34191033 · one of two readings recorded this
fasted carbohydrate oxidation
no effect, p = 0.588
neither carbohydrate nor lipid oxidation in the fasted state was different between INT and CON [P = 0.588 and P = 0.787, respectively]
PMID 34191033 · one of two readings recorded this
fasted lipid oxidation
no effect, p = 0.787
neither carbohydrate nor lipid oxidation in the fasted state was different between INT and CON [P = 0.588 and P = 0.787, respectively]
PMID 34191033 · one of two readings recorded this
fasting respiratory exchange ratio
no effect, p = 0.297
Basal metabolic rates and fasting RERs were similar between INT and CON (P = 0.824 and P = 0.297, respectively
PMID 34191033 · one of two readings recorded this
gross exercise efficiency (GEE)
no effect, p = 0.419
GEE did not differ between conditions (P = 0.419; Figure 5I)
PMID 34191033 · one of two readings recorded this
intrahepatic lipid content
no effect, p = 0.624
Intrahepatic lipid content was measured noninvasively by 1H-MRS and did not differ between INT (2.8%; 0.8%–4.8%) and CON (2.7%; 1.1%–4.3%; P = 0.624)
PMID 34191033 · one of two readings recorded this
maximal uncoupled respiration (State 3U)
no effect, p = 0.495
Maximal uncoupled respiration (State 3U), a reflection of the maximal capacity of the electron transport chain, did not differ between INT and CON (P = 0.495; Figure 4E)
PMID 34191033 · one of two readings recorded this
mitochondrial proton leak (State 4o)
no effect, p = 0.888
mitochondrial proton leak (State 4o) was assessed through the addition of oligomycin and did not differ between INT and CON (P = 0.888; Figure 4F)
PMID 34191033 · one of two readings recorded this
net exercise efficiency (NEE)
no effect, p = 0.636
NEE (i.e., GEE corrected for the BMR) was also not different between conditions (P = 0.636; Figure 5J)
PMID 34191033 · one of two readings recorded this
plasma free fatty acids
no effect, p = 0.812
Concentrations of FFA showed no differences between INT (496 μmol/L; 95% CI: 397, 595 μmol/L) and CON (512 μmol/L; 95% CI: 416, 609 μmol/L; P = 0.812]
PMID 34191033 · one of two readings recorded this
plasma glucose
no effect, p = 0.223
Glucose concentrations did not differ for INT (5.87 mmol/L; 95% CI: 5.57, 6.16 mmol/L) and CON (5.76 mmol/L; 95% CI: 5.52, 6.01 mmol/L; P = 0.223)
PMID 34191033 · one of two readings recorded this
plasma insulin
no effect, p = 0.807
insulin levels were not different between INT (9.41 mU/L; 95% CI: 4.18, 14.7 mU/L) and CON (9.12 mU/L; 95% CI: 5.40, 12.8 mU/L; P = 0.807)
PMID 34191033 · one of two readings recorded this
plasma triglycerides
no effect, p = 0.266
plasma TG levels were not different between INT (0.830 mmol/L; IQR, 0.675–1.03 mmol/L) and CON (0.990 mmol/L; IQR, 0.610–1.43 mmol/L; P = 0.266)
PMID 34191033 · one of two readings recorded this
RAND-36 other 8 domains
no effect, p = 0.05
the other 8 out of 9 domains of the RAND-36 did not show any differences between INT and CON on Day 29 (P ≥ 0.05; Figure 6)
PMID 34191033 · one of two readings recorded this
RAND-36 perceived physical functioning domain
increases, p = 0.031, n = 12
significantly higher scores were observed for the perceived physical functioning domain in INT (92.0; IQR, 90.0–100) as compared to CON (90.0; IQR, 86.3–93.8; n = 12; P = 0.031)
PMID 34191033 · one of two readings recorded this
skeletal muscle acylcarnitine subgroups
no effect, p = 0.05, n = 11
no differences were observed in the concentrations of acylcarnitine subgroups between INT and CON (P ≥ 0.05;; n = 11)
PMID 34191033 · one of two readings recorded this
skeletal muscle ADP riboside (ADPr)
no effect, p = 0.413, n = 11
with no differences observed in ADPr levels between INT and CON (P = 0.413; n = 11; Figure 2)
PMID 34191033 · one of two readings recorded this
skeletal muscle methyl-nicotinamide (MeNAM)
increases, p = 0.001
revealed significantly higher MeNAM concentrations in INT compared to CON (P = 0.001; Figure 2)
PMID 34191033 · one of two readings recorded this
skeletal muscle NAAD
no effect, p = 0.262, n = 11
which was not different between INT and CON (P = 0.262; n = 11; Figure 2)
PMID 34191033 · one of two readings recorded this
skeletal muscle NAD(H)
no effect, p = 0.389, n = 11
The respective reduced forms, NAD(H) and NAD(P)H, also did not differ between conditions (P = 0.389 and P = 0.365 respectively; n = 11; Figure 2)
PMID 34191033 · one of two readings recorded this
skeletal muscle NAD+ level
no effect, p = 0.123
These analyses showed that NAD+ levels were similar between INT and CON (P = 0.123)
PMID 34191033 · one of two readings recorded this
skeletal muscle NAD(P)H
no effect, p = 0.365, n = 11
The respective reduced forms, NAD(H) and NAD(P)H, also did not differ between conditions (P = 0.389 and P = 0.365 respectively; n = 11; Figure 2)
PMID 34191033 · one of two readings recorded this
skeletal muscle NAD(P)+
no effect, p = 0.833, n = 11
which did not differ between conditions (P = 0.833; n = 11; Figure 2)
PMID 34191033 · one of two readings recorded this
SPPB balance test
no effect, p = 0.999
Scores for the balance test, the walking speed, and the chair-rise test were similar between INT and CON (P > 0.999, P = 0.500, and P = 0.489, respectively)
PMID 34191033 · one of two readings recorded this
SPPB chair-rise test
no effect, p = 0.489
Scores for the balance test, the walking speed, and the chair-rise test were similar between INT and CON (P > 0.999, P = 0.500, and P = 0.489, respectively)
PMID 34191033 · one of two readings recorded this
SPPB overall score
no effect, p = 0.999
The overall score on the SPPB was also not different between INT (11.0; IQR, 10.00–11.5) and CON (11.0; IQR, 9.50–12.0; P > 0.999)
PMID 34191033 · one of two readings recorded this
SPPB walking speed
no effect, p = 0.5
Scores for the balance test, the walking speed, and the chair-rise test were similar between INT and CON (P > 0.999, P = 0.500, and P = 0.489, respectively)
PMID 34191033 · one of two readings recorded this
State 3 respiration, complex I-linked lipid substrates (malate + octanoyl-carnitine)
no effect, p = 0.882
Also, the assessment of ADP-stimulated (State 3) respiration fueled by complex I-linked substrates (malate and octanoyl-carnitine; Figure 4B, P = 0.882) did not reveal any differences between INT and CON
PMID 34191033 · one of two readings recorded this
State 3 respiration, malate + glutamate (MG)
no effect, p = 0.054
If anything, state 3 respiration upon MG tended to be lower in INT compared with CON (P = 0.054; Figure 4C)
PMID 34191033 · one of two readings recorded this
State 3 respiration, malate + glutamate + succinate
no effect, p = 0.388
or malate + glutamate + succinate (P = 0.388; Figure 4D)
PMID 34191033 · one of two readings recorded this
State 3 respiration, malate + octanoyl-carnitine + glutamate + succinate
no effect, p = 0.716
malate + octanoyl-carnitine + glutamate + succinate (P = 0.716)
PMID 34191033 · one of two readings recorded this
State 3 respiration, malate + octanoyl-carnitine + glutamate
no effect, p = 0.753
State 3 respiration upon parallel electron input into complexes I and II showed no differences between INT and CON with the substrate combinations malate + octanoyl-carnitine + glutamate (P = 0.753)
PMID 34191033 · one of two readings recorded this
supplement compliance (sachets consumed)
For the supplementation with precursors (INT), 100% of all sachets were consumed, compared to 99% (range, 97%–100%) in the control condition (CON)
PMID 34191033 · one of two readings recorded this
systolic blood pressure
no effect, p = 0.821
Day 1 | 140 (131–148) | 141 (131–151) | 0.821
PMID 34191033 · one of two readings recorded this
systolic blood pressure
no effect, p = 0.741
Day 15 | 140 (131–149) | 139 (129–148) | 0.741
PMID 34191033 · one of two readings recorded this
systolic blood pressure
no effect, p = 0.877
Day 29 | 136 (128–145) | 137 (130–143) | 0.877
PMID 34191033 · one of two readings recorded this
total energy expenditure during submaximal cycling
no effect, p = 0.103
The total energy expenditure during cycling did not differ between INT and CON (P = 0.103; Figure 5E)
PMID 34191033 · one of two readings recorded this
vastus lateralis muscle volume
no effect, p = 0.45, n = 11
Muscle volume of the m. vastus lateralis, assessed by MRI, was not different for INT (1700 cm3; 1440–1960 cm3) compared to CON (1710 cm3; 1450–1980 cm3; n = 11; P = 0.450)
PMID 34191033 · one of two readings recorded this
ATP + ADP
increases, p = 0.029
This difference is significant on Day 5, when the RiaGev group was 7.3% higher than the Placebo group (p = 0.029)
PMID 35684021 · one of two readings recorded this
blood NAD+ concentration
increases, p = 0.044
At day 5, the NAD+ concentration in RiaGev group was significantly higher than that at Day 1, a 10.4% increase (p = 0.034), which is also significantly higher than that in the placebo group (p = 0.044)
PMID 35684021 · one of two readings recorded this
blood NAD+ concentration
increases, p = 0.034
At day 5, the NAD+ concentration in RiaGev group was significantly higher than that at Day 1, a 10.4% increase (p = 0.034), which is also significantly higher than that in the placebo group (p = 0.044)
PMID 35684021 · one of two readings recorded this
blood NAD+ concentration
unclear, p = 0.07
At Day 8, there is also a trending significant increase of 6.4% in NAD+ concentration over baseline (p = 0.07)
PMID 35684021 · one of two readings recorded this
blood NAD+ + NADP+ concentration
increases, p = 0.029
When combined, NAD+ + NADP+ concentrations observed at Days 5 and 8 were significantly higher than that in Placebo (p ≤ 0.029, Figure 2c)
PMID 35684021 · one of two readings recorded this
blood NAD+ + NADP+ concentration
increases, p = 0.032
significant within-group concentration increases of 9.4%, 14.8% and 9.7% reported within RiaGev group at Days 3, 5, and 8 respectively (p ≤ 0.032)
PMID 35684021 · one of two readings recorded this
blood NAD+ + NADP+ concentration
increases, p = 0.032
significant within-group concentration increases of 9.4%, 14.8% and 9.7% reported within RiaGev group at Days 3, 5, and 8 respectively (p ≤ 0.032)
PMID 35684021 · one of two readings recorded this
blood NAD+ + NADP+ concentration
increases, p = 0.032
significant within-group concentration increases of 9.4%, 14.8% and 9.7% reported within RiaGev group at Days 3, 5, and 8 respectively (p ≤ 0.032)
PMID 35684021 · one of two readings recorded this
blood NADP+ concentration
increases, p = 0.04
The NADP+ concentrations for the RiaGev group are also significantly greater than that of Placebo group at Day 5 and 8 (p ≤ 0.04)
PMID 35684021 · one of two readings recorded this
blood NADP+ concentration
increases, p = 0.008
Significant within-group increases of 19.1%, 27.6%, and 19.6% were recorded with RiaGev group at Days 3, 5, and 8 over baseline, respectively (p ≤ 0.008)
PMID 35684021 · one of two readings recorded this
blood NADP+ concentration
increases, p = 0.008
Significant within-group increases of 19.1%, 27.6%, and 19.6% were recorded with RiaGev group at Days 3, 5, and 8 over baseline, respectively (p ≤ 0.008)
PMID 35684021 · one of two readings recorded this
blood NADP+ concentration
increases, p = 0.008
Significant within-group increases of 19.1%, 27.6%, and 19.6% were recorded with RiaGev group at Days 3, 5, and 8 over baseline, respectively (p ≤ 0.008)
PMID 35684021 · one of two readings recorded this
blood NADP+ + NADPH concentration
increases, p = 0.05
the nicotinamide adenine dinucleotide phosphates in the RiaGev group increased significantly at 8.3%, 22.5%, and 12.9% at Days 3, 5, and 8, respectively, compared to the Placebo group and over the baseline (p < 0.05)
PMID 35684021 · one of two readings recorded this
blood NADP+ + NADPH concentration
increases, p = 0.05
the nicotinamide adenine dinucleotide phosphates in the RiaGev group increased significantly at 8.3%, 22.5%, and 12.9% at Days 3, 5, and 8, respectively, compared to the Placebo group and over the baseline (p < 0.05)
PMID 35684021 · one of two readings recorded this
blood NADP+ + NADPH concentration
increases, p = 0.05
the nicotinamide adenine dinucleotide phosphates in the RiaGev group increased significantly at 8.3%, 22.5%, and 12.9% at Days 3, 5, and 8, respectively, compared to the Placebo group and over the baseline (p < 0.05)
PMID 35684021 · one of two readings recorded this
blood NADPH concentration
no effect, p = 0.08
There was only a trending increase in NADPH in the RiaGev group compared to the Placebo group (p >0.08)
PMID 35684021 · one of two readings recorded this
CIS concentration improvement
increases, p = 0.014
Concentration in the RiaGev group also improved significantly by 22.9% (p = 0.014), 19.8% (p = 0.012) and 14.3% (p = 0.118) at Days 3, 5, and 8, respectively
PMID 35684021 · one of two readings recorded this
CIS concentration improvement
increases, p = 0.012
Concentration in the RiaGev group also improved significantly by 22.9% (p = 0.014), 19.8% (p = 0.012) and 14.3% (p = 0.118) at Days 3, 5, and 8, respectively
PMID 35684021 · one of two readings recorded this
CIS concentration improvement
unclear, p = 0.118
Concentration in the RiaGev group also improved significantly by 22.9% (p = 0.014), 19.8% (p = 0.012) and 14.3% (p = 0.118) at Days 3, 5, and 8, respectively
PMID 35684021 · one of two readings recorded this
CIS motivation improvement
unclear, p = 0.13
the RiaGev group improved by 20.4% (p = 0.13), 22.2% (p = 0.015), and 14% (p = 0.163) at Days 3, 5, and 8, respectively
PMID 35684021 · one of two readings recorded this
CIS motivation improvement
increases, p = 0.015
the RiaGev group improved by 20.4% (p = 0.13), 22.2% (p = 0.015), and 14% (p = 0.163) at Days 3, 5, and 8, respectively
PMID 35684021 · one of two readings recorded this
CIS motivation improvement
unclear, p = 0.163
the RiaGev group improved by 20.4% (p = 0.13), 22.2% (p = 0.015), and 14% (p = 0.163) at Days 3, 5, and 8, respectively
PMID 35684021 · one of two readings recorded this
CIS physical fatigue improvement
increases
At Days 3, 5, and 8, the physical fatigue improved by 24.3% (p = 0.003) vs. 13.6% (p = 0.041), 21.2% (p = 0.009) vs. 11.6% (p = 0.08), 15.1% (p = 0.132) vs. 7.4% (p = 0.17) in the RiaGev vs. Placebo groups, respectively
PMID 35684021 · one of two readings recorded this
CIS physical fatigue improvement
increases
At Days 3, 5, and 8, the physical fatigue improved by 24.3% (p = 0.003) vs. 13.6% (p = 0.041), 21.2% (p = 0.009) vs. 11.6% (p = 0.08), 15.1% (p = 0.132) vs. 7.4% (p = 0.17) in the RiaGev vs. Placebo groups, respectively
PMID 35684021 · one of two readings recorded this
CIS physical fatigue improvement
increases
At Days 3, 5, and 8, the physical fatigue improved by 24.3% (p = 0.003) vs. 13.6% (p = 0.041), 21.2% (p = 0.009) vs. 11.6% (p = 0.08), 15.1% (p = 0.132) vs. 7.4% (p = 0.17) in the RiaGev vs. Placebo groups, respectively
PMID 35684021 · one of two readings recorded this
CIS total score improvement
increases
At Days 3, 5, and 8, the total CIS scores were improved by 21.5% (p = 0.04) vs. 10.4% (p = 0.07), 18.3% (p = 0.014) vs. 6.2% (p = 0.049), and 12.7% (p = 0.15) vs. 4.1% (p = 0.361) in the RiaGev vs. the Placebo group, respectively
PMID 35684021 · one of two readings recorded this
CIS total score improvement
increases
At Days 3, 5, and 8, the total CIS scores were improved by 21.5% (p = 0.04) vs. 10.4% (p = 0.07), 18.3% (p = 0.014) vs. 6.2% (p = 0.049), and 12.7% (p = 0.15) vs. 4.1% (p = 0.361) in the RiaGev vs. the Placebo group, respectively
PMID 35684021 · one of two readings recorded this
CIS total score improvement
increases
At Days 3, 5, and 8, the total CIS scores were improved by 21.5% (p = 0.04) vs. 10.4% (p = 0.07), 18.3% (p = 0.014) vs. 6.2% (p = 0.049), and 12.7% (p = 0.15) vs. 4.1% (p = 0.361) in the RiaGev vs. the Placebo group, respectively
PMID 35684021 · one of two readings recorded this
OGTT blood glucose iAUC
decreases, p = 0.013
the blood glucose iAUC level of RiaGev group at Day 8 was significantly lower compared to Day 1 (1700.42 vs. 662.50, respectively, p = 0.013)
PMID 35684021 · one of two readings recorded this
OGTT glucose peak at 15 min
no effect
despite the glucose peak remaining the same (116 vs. 114 mg/dL at 15 min post-prandial at Day 8 vs. Day 1, respectively, Figure 3a)
PMID 35684021 · one of two readings recorded this
OGTT insulin peak
increases
the insulin peak on Day 8 was higher than on Day 1 (74 vs. 67 μU/mL, respectively, Figure 3c)
PMID 35684021 · one of two readings recorded this
OGTT overall insulin level
no effect, p = 0.793
the overall insulin level of RiaGev group at Day 8 was not significantly different from Day 1 (p = 0.793)
PMID 35684021 · one of two readings recorded this
OGTT total blood glucose AUC (0-120 min)
no effect
the Placebo group did not change significantly (12,041.55 on Day 1 vs. 11,914.8 on Day 8)
PMID 35684021 · one of two readings recorded this
OGTT total blood glucose AUC (0-120 min)
decreases
RiaGev reduced blood glucose AUC 4.92% (from 12,771.15 on Day 1 to 12,143.17 on Day 8) after 7-day supplementation
PMID 35684021 · one of two readings recorded this
supplement compliance
The compliance for taking RiaGev and Placebo supplementations is 100%
PMID 35684021 · one of two readings recorded this
total glutathione (GSH + GSSG)
increases, p = 0.016
There was a significant increase of total glutathione (GSH + GSSG) at Day 3 and 5 (10.2% and 11.6%, respectively) in the RiaGev group over baseline (p ≤ 0.016)
PMID 35684021 · one of two readings recorded this
total glutathione (GSH + GSSG)
increases, p = 0.016
There was a significant increase of total glutathione (GSH + GSSG) at Day 3 and 5 (10.2% and 11.6%, respectively) in the RiaGev group over baseline (p ≤ 0.016)
PMID 35684021 · one of two readings recorded this
waking salivary cortisol
decreases, p = 0.044
There was a significant between-group difference in waking salivary cortisol at Day 5 and Day 8, where the RiaGev group displayed lower levels of cortisol than the placebo group (p = 0.044)
PMID 35684021 · one of two readings recorded this